LB Pharmaceuticals Sees Schizophrenia Drug Derivative As New Option For US Patients

 
• By Joseph Haas
  
LB Pharmaceuticals hopes to bring a new formulation of an old schizophrenia drug to market (Shutterstock)

More from Clinical Trials

More from Therapy Areas